Company intelligence / Profile preview
Cell Source
New York, New York, United Statescell-source.com ↗
- Ownership
- Public · CLCS
- Employees
- ~1
- Development stage
- Other
01
Overview
Cell Source's Veto Cell technology is in pre-clinical phase with data demonstrating results in allogeneic hematopoietic stem cell transplantation by enabling haploidentical stem cell transplants under mild conditioning regimens.[2]
- Therapeutic areas
- HematologyImmunologyEndocrinologyNeurologyOncology
- Modalities
- Cell therapyCAR-T cell therapyStem cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Financials
- Market cap
- $35.3M
- Total revenue
- $0
- Enterprise value
- $45.3M
Beyond the preview
Go deeper on Cell Source.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cell Source.